Our vision is to develop superior mAb mixture therapeutics to improve the lives of patients with cancer and other diseases with significant unmet medical needs.

We are a leading clinical late-stage antibody oncology-focused company with a differentiated monoclonal antibody, or mAb, mixture product pipeline with significant clinical potential and commercial opportunities. Our novel biologic approach is uniquely designed to address tumor diversity and resistance by combining multiple antibodies in a single drug product.